GILEAD SCIENCES, INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 28/100
What the filing says
Gilead completed acquisitions of Arcellx ($7.0B IPR&D), Tubulis ($3.1B upfront, $3.15B total), and Ouro Medicines ($1.0B IPR&D, $1.675B upfront with 50% partner Lakefront), recording $11.2B in acquired IPR&D expenses in Q2 2026. Core product sales (excluding Veklury) grew 10% to $7.6B; HIV sales rose 12% to $5.7B. GAAP diluted EPS was $(8.45) vs. $1.56 YoY; non-GAAP diluted EPS was $(6.75) vs. $2.01 YoY. Cash declined from $10.6B to $3.2B due to $11.3B acquisition outflows. FY2026 guidance updated: product sales $30.1–$30.4B (base business raised), GAAP diluted loss EPS $(3.75)–$(3.40).
Why this rating
Large acquisition outlay ($11.3B H1 2026) relative to ~$103B market cap (~11%), but IPR&D charges are non-cash accounting. Core business growing 10%; cash position diminished but operating cash flow solid. Not transformational relative to company size.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.